Endo Submits "Complete Response" For Oxymorphone ER
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing includes data from two additional clinical trials in opioid-naive and opioid-experienced patients, company says.
You may also be interested in...
Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs
The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.
Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs
The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.
Endo’s Oxymorphone Solid Tablet Could Be Unscathed By Palladone Withdrawal
Purdue’s withdrawal of its opiate Palladone may not impact Endo’s pending oxymorphone product because of formulation differences, the company says. Endo hopes to avoid marketing restrictions for oxymorphone based on a broad clinical development program.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: